Blockchain Registration Transaction Record

GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness

GeoVax Labs, Inc. is developing GEO-MVA to combat Clade 1 Mpox, a highly virulent strain with a fatality rate of 3% - 10%. This initiative aims to strengthen vaccine supply chains and enhance global readiness for infectious diseases. Learn more about GeoVax's efforts to address vaccine shortages and manufacturing challenges.

This news matters as it highlights the importance of diversifying vaccine manufacturing capabilities to ensure timely access to critical vaccines. The emergence of Clade 1 Mpox underscores the need for immediate action to prevent supply chain disruptions and vaccine shortages, especially in the face of a surging demand for vaccines.